Orthofix International N.v Stock Earnings Reports

Orthofix reported a solid start to 2026 with Q1 net sales of $196.4 million, a pro forma constant-currency increase of 3% year-over-year. Management highlighted steady execution, improved stability after distributor transitions, and a sharper commercial focus following spine leadership realignment. Segment performance: Global Spine Fixation grew ~6% (U.S. +4%), Therapeutic Solutions (formerly Bone Growth Therapies) grew 5% and outperformed the market, and Global Limb Reconstruction grew 3% (U.S. flat). Top 30 U.S. distributors delivered strong growth (27% YoY), driven by adoption of the 7D FLASH navigation system. Key product and pipeline catalysts include the full-market VIRATA launch in H2 2026, continued rollouts of TrueLok Elevate and Fitbone, and broader adoption of the 7D ecosystem. Financials: pro forma non-GAAP adjusted gross margin was 70.7% (up 40 bps), adjusted EBITDA was $9.7 million, and cash totaled $120.9 million (increase driven by financing activity). Management reaffirmed full-year 2026 guidance: net sales $850M–$860M (~5.5% growth midpoint), adjusted EBITDA $95M–$98M, and positive free cash flow for the year (excluding potential legal settlements). Near-term outlook: management expects acceleration through the year (approx. 5% growth 1H and ~6% 2H), continued margin expansion, and positive contribution from recent and upcoming product launches. Risks called out include macro/operational considerations and standard SEC-forward-looking disclaimers, while geopolitical impacts (Middle East) were described as minimal and largely timing-related.